NUBEQA now has indications in both metastatic hormone-sensitive prostate cancer (mHSPC) and non-metastatic castration-resistant prostate cancer (nmCRPC)1Today’s approval under the FDA’s Real-Time Oncology Review (RTOR) pilot program was based on the pivotal Phase III ARASENS trial, which showed a significant overall.
16.06.2022 - Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced the appointment of Kelley Dealhoy as Senior Vice President and Chief Business Officer. Ms. Dealhoy brings 20 years of life science leadership experience to the role, and her .
KINGSTON, Jamaica - To better facilitate the process of obtaining licences in the cannabis industry, key amendments to the legislation are expected to be made in the next few months.
This was disclose.